Personal Care Related News

Amyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based Products

EMERYVILLE, Calif. and BOSTON, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has completed a subsequent collaboration agreement with Ginkgo Bioworks, which is expected to be approved by the boards of [...]

Intrexon Responds to Short-Sellers’ Report

Holders of Intrexon Corporation stock are watching their portfolios carefully in wake of the anonymous publication last Thursday of a short-seller report that alleges the company’s technology is less cutting-edge than it claims and that its revenues are exaggerated. On [...]

Harvest Capital Strategies Raises $245M Fund for Companies Utilizing Tools of Intrexon

Harvest Capital Strategies announced Tuesday that it has raised $245 million to specifically finance companies utilizing the synthetic biology tools of Intrexon Corporation. This is big news for Intrexon, whose subsidiaries and their genetically modified products have been prominent in [...]

From BIOtech to bioTECH: Meet Serial Entrepreneur Randal Kirk, CEO of Intrexon

There will be a lot of synthetic biologists at the upcoming conference, and a lot of entrepreneurs hoping to scale their company to greatness and riches (often these two are combined into the same person). It is, however, a difficult [...]

Intrexon Stock Offering Generates $230 Million

The synthetic biology company Intrexon Corporation recently announced the closing of its public stock offering, which garnered $230 million dollars from the sale of more than 5.5 million shares in the course of a week. This is just the latest [...]

3 Potential New Molecules for Amyris’ Portfolio in 2014

Synthetic biology pioneer Amyris may have spent much of last year slashing wasteful spending and reevaluating its strategic vision, but it also achieved several major farnesene production milestones at its lone commercial facility in Brotas, Brazil. While the company will continue to [...]